본문으로 건너뛰기
← 뒤로

Quantification of DNA Methylation for Diagnosis and Monitoring of Hepatocellular Carcinoma.

1/5 보강
Journal of the American College of Surgeons 2026 Vol.242(4) p. 934-946
Retraction 확인
출처

PICO 자동 추출 (휴리스틱, conf 2/4)

유사 논문
P · Population 대상 환자/모집단
18 patients with HCC and 4 noncancer controls.
I · Intervention 중재 / 시술
추출되지 않음
C · Comparison 대조 / 비교
추출되지 않음
O · Outcome 결과 / 결론
[CONCLUSIONS] HBMV is a sensitive and biologically grounded biomarker for HCC diagnosis, prognosis, and real-time disease monitoring. These findings support further prospective evaluation of HBMV as a noninvasive tool for clinical surveillance and assessment of treatment response.

Javanshir S, Angeli-Pahim I, Iyengar P, Chambers A, Smarandache IM, Ganguli R, Hughes S, Sahin I, Duarte S, Zarrinpar A

📝 환자 설명용 한 줄

[BACKGROUND] Hepatocellular carcinoma (HCC) remains one of the leading causes of cancer-related mortality worldwide, with early detection and accurate monitoring of tumor burden being critical for imp

🔬 핵심 임상 통계 (초록에서 자동 추출 — 원문 검증 권장)
  • 연구 설계 cohort study

이 논문을 인용하기

BibTeX ↓ RIS ↓
APA Javanshir S, Angeli-Pahim I, et al. (2026). Quantification of DNA Methylation for Diagnosis and Monitoring of Hepatocellular Carcinoma.. Journal of the American College of Surgeons, 242(4), 934-946. https://doi.org/10.1097/XCS.0000000000001792
MLA Javanshir S, et al.. "Quantification of DNA Methylation for Diagnosis and Monitoring of Hepatocellular Carcinoma.." Journal of the American College of Surgeons, vol. 242, no. 4, 2026, pp. 934-946.
PMID 41575457

Abstract

[BACKGROUND] Hepatocellular carcinoma (HCC) remains one of the leading causes of cancer-related mortality worldwide, with early detection and accurate monitoring of tumor burden being critical for improving patient outcomes. Existing biomarkers such as alpha-fetoprotein (AFP) have limited sensitivity and specificity, underscoring the need for more reliable diagnostic and prognostic tools.

[STUDY DESIGN] In this retrospective cohort study, we developed the HCC beta methylation value (HBMV) using 2 targeted CpG amplicon panels, HBMV-6 and HBMV-28. HBMV values were calculated by summing beta methylation values across predefined loci and validated using The Cancer Genome Atlas, 15 Gene Expression Omnibus datasets comprising more than 1,400 liver tissue samples, and a prospective plasma cohort including 18 patients with HCC and 4 noncancer controls. Diagnostic, prognostic, and longitudinal performance was compared with AFP.

[RESULTS] Both HBMV panels accurately distinguished HCC from noncancer liver tissue, achieving area under the receiver operating characteristic curve values greater than 0.9 in tissue and greater than 0.8 in plasma. Across independent tissue cohorts, HBMV-28 values increased stepwise from normal liver to cirrhosis, dysplasia, and HCC. Higher HBMV values were associated with larger tumor size and worse overall survival. In longitudinal plasma analyses, HBMV decreased after surgical resection or transplantation and increased during disease progression, effectively distinguishing progression from nonprogression with an area under the curve up to 0.87. In contrast, AFP demonstrated modest sensitivity and failed to reliably track treatment response.

[CONCLUSIONS] HBMV is a sensitive and biologically grounded biomarker for HCC diagnosis, prognosis, and real-time disease monitoring. These findings support further prospective evaluation of HBMV as a noninvasive tool for clinical surveillance and assessment of treatment response.

MeSH Terms

Humans; Carcinoma, Hepatocellular; Liver Neoplasms; DNA Methylation; Male; Female; Middle Aged; Retrospective Studies; Biomarkers, Tumor; Aged; Prognosis; alpha-Fetoproteins; Adult; ROC Curve